Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Open Access
- 15 October 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (20) , 5143-5152
Abstract
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a critical need for novel therapies. Our goal was to determine whether PARP inhibition could sensitize SCLC cells to ionizing radiation (IR) and if so, to determine the contribution of PARP trapping to radiosensitization. Experimental Design: Short-term viability assays and clonogenic survival assays (CSA) were used to assess radiosensitization in 6 SCLC cell lines. Doses of veliparib and talazoparib with equivalent enzymatic inhibitory activity but differing PARP trapping activity were identified and compared in CSAs. Talazoparib, IR, and their combination were tested in three patient-derived xenograft (PDX) models. Results: Talazoparib radiosensitized 5 of 6 SCLC cell lines in short-term viability assays and confirmed in 3 of 3 cell lines by CSAs. Concentrations of 200 nmol/L talazoparib and 1,600 nmol/L veliparib similarly inhibited PAR polymerization; however, talazoparib exhibited greater PARP trapping activity that was associated with superior radiosensitization. This observation further correlated with an increased number of double-stranded DNA breaks induced by talazoparib as compared with veliparib. Finally, a dose of 0.2 mg/kg talazoparib in vivo caused tumor growth inhibition in combination with IR but not as a single agent in 3 SCLC PDX models. Conclusions: PARP inhibition effectively sensitizes SCLC cell lines and PDXs to IR, and PARP trapping activity enhances this effect. PARP inhibitors, especially those with high PARP trapping activity, may provide a powerful tool to improve the efficacy of radiotherapy in SCLC. Clin Cancer Res; 24(20); 5143–52. ©2018 AACR.Keywords
All Related Versions
Funding Information
- HHS | NIH | National Cancer Institute (NCI) (UL1TR00457)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA008748)
- HHS | NIH | National Cancer Institute (NCI) (R01 CA197936)
- HHS | NIH | National Cancer Institute (NCI) (U54 OD020355 01)
- Conquer Cancer Foundation (CCF)
- Radiological Society of North America (RSNA)
- Lung Cancer Research Foundation (LCRF)
This publication has 32 references indexed in Scilit:
- In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer CellsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerNature Genetics, 2012
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Cancer Discovery, 2012
- Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing RadiationMolecular Cancer Therapeutics, 2011
- A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by CultureIn vitroCancer Research, 2009
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic PotentialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerCancer Research, 2008
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and EtoposideNew England Journal of Medicine, 1999